Secondary amyloidosis differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
(14 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/ | [[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Secondary_amyloidosis#Overview]] | ||
{{CMG}}; {{AE}} {{Sahar}} | {{CMG}}; {{AE}} {{HK}} {{Sahar}} | ||
== Overview == | == Overview == | ||
Secondary amyloidosis needs to be differentiated from other [[conditions]] causing [[nephrotic syndrome]], [[hepatosplenomegaly]], and [[peripheral neuropathy]]. | Secondary amyloidosis needs to be differentiated from other [[conditions]] causing [[nephrotic syndrome]], [[hepatosplenomegaly]], and [[peripheral neuropathy]]. | ||
==Differentiating Amyloidosis from other Diseases == | ==Differentiating Amyloidosis from other Diseases == | ||
Secondary amyloidosis needs to be differentiated from other [[conditions]] causing [[nephrotic syndrome]], [[hepatosplenomegaly]], and [[peripheral neuropathy]]. | *Secondary amyloidosis needs to be differentiated from other [[conditions]] causing [[nephrotic syndrome]], [[hepatosplenomegaly]], and [[peripheral neuropathy]]. | ||
*Also, secondary amyloidosis should be differentiated from other types of [[amyloidosis]], including:<ref name="Real de AsuaGalvan2014">{{cite journal|last1=Real de Asua|first1=Diego|last2=Galvan|first2=Jose Maria|last3=Filigghedu|first3=Maria Teresa|last4=Trujillo|first4=Davinia|last5=Costa|first5=Ramon|last6=Cadinanos|first6=Julen|title=Systemic AA amyloidosis: epidemiology, diagnosis, and management|journal=Clinical Epidemiology|year=2014|pages=369|issn=1179-1349|doi=10.2147/CLEP.S39981}}</ref><ref name="MolleeRenaut2014">{{cite journal|last1=Mollee|first1=P.|last2=Renaut|first2=P.|last3=Gottlieb|first3=D.|last4=Goodman|first4=H.|title=How to diagnose amyloidosis|journal=Internal Medicine Journal|volume=44|issue=1|year=2014|pages=7–17|issn=14440903|doi=10.1111/imj.12288}}</ref> | |||
**[[AL amyloidosis|Immunoglobulin light chain amyloidosis]] | |||
**[[Hereditary amyloidosis]] | |||
**[[Beta2-microglobulin related amyloidosis|Dialysis-related amyloidosis]] | |||
**[[Senile systemic amyloidosis|Age-related (senile) systemic amyloidosis]] | |||
{| class="wikitable" | |||
! rowspan="2" style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|Amyloisosis subtype}} | |||
! rowspan="2" style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|Protein}} | |||
! colspan="3" style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|Organ involvement (%)}} | |||
|- | |||
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|Kidney}} | |||
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|Liver}} | |||
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|Heart}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |[[Primary amyloidosis|Primary]] | |||
|Monoclonal immunoglobulin light chains | |||
|50-100 | |||
|10-25 | |||
|50-100 | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Secondary | |||
|Serum amyloid A | |||
|50-100 | |||
|<10 | |||
|_ | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |[[Familial amyloidosis|Hereditary]] | |||
|Transthyretin (mutated) | |||
|<10 | |||
|_ | |||
|25-50 | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |DRA ([[dialysis related amyloidosis]]) | |||
|Beta‐2 microglobulin | |||
|_ | |||
|_ | |||
|_ | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |[[Senile systemic amyloidosis|Senile systemic (cardiac) amyloidosis]] | |||
|Transthyretin (wild type) | |||
|_ | |||
|_ | |||
|50-100 | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |[[Gelsolin related amyloidosis|Meretoja syndrome]] | |||
|Gelsolin | |||
|_ | |||
|_ | |||
|_ | |||
|} | |||
*Tables below provide information on the differential diagnosis of secondary amyloidosis. | |||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
Line 132: | Line 183: | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Therapy}} | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Therapy}} | ||
|- | |- | ||
| rowspan="9" style= "padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Nephrotic Syndrome and Renal Failure''' | | rowspan="9" style= "padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Nephrotic Syndrome and Renal Failure'''<ref name="pmid15327378">{{cite journal |vauthors=Rivera F, López-Gómez JM, Pérez-García R |title=Clinicopathologic correlations of renal pathology in Spain |journal=Kidney Int. |volume=66 |issue=3 |pages=898–904 |date=September 2004 |pmid=15327378 |doi=10.1111/j.1523-1755.2004.00833.x |url=}}</ref><ref name="pmid9370176">{{cite journal |vauthors=Haas M, Meehan SM, Karrison TG, Spargo BH |title=Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997 |journal=Am. J. Kidney Dis. |volume=30 |issue=5 |pages=621–31 |date=November 1997 |pmid=9370176 |doi= |url=}}</ref><ref name="pmid15327379">{{cite journal |vauthors=Simon P, Ramee MP, Boulahrouz R, Stanescu C, Charasse C, Ang KS, Leonetti F, Cam G, Laruelle E, Autuly V, Rioux N |title=Epidemiologic data of primary glomerular diseases in western France |journal=Kidney Int. |volume=66 |issue=3 |pages=905–8 |date=September 2004 |pmid=15327379 |doi=10.1111/j.1523-1755.2004.00834.x |url=}}</ref><ref name="pmid10793022">{{cite journal |vauthors=Braden GL, Mulhern JG, O'Shea MH, Nash SV, Ucci AA, Germain MJ |title=Changing incidence of glomerular diseases in adults |journal=Am. J. Kidney Dis. |volume=35 |issue=5 |pages=878–83 |date=May 2000 |pmid=10793022 |doi= |url=}}</ref><ref name="pmid16968733">{{cite journal |vauthors=Malafronte P, Mastroianni-Kirsztajn G, Betônico GN, Romão JE, Alves MA, Carvalho MF, Viera Neto OM, Cadaval RA, Bérgamo RR, Woronik V, Sens YA, Marrocos MS, Barros RT |title=Paulista Registry of glomerulonephritis: 5-year data report |journal=Nephrol. Dial. Transplant. |volume=21 |issue=11 |pages=3098–105 |date=November 2006 |pmid=16968733 |doi=10.1093/ndt/gfl237 |url=}}</ref><ref name="pmid14989627">{{cite journal |vauthors=Bahiense-Oliveira M, Saldanha LB, Mota EL, Penna DO, Barros RT, Romão-Junior JE |title=Primary glomerular diseases in Brazil (1979-1999): is the frequency of focal and segmental glomerulosclerosis increasing? |journal=Clin. Nephrol. |volume=61 |issue=2 |pages=90–7 |date=February 2004 |pmid=14989627 |doi= |url=}}</ref><ref name="pmid15327376">{{cite journal |vauthors=Gesualdo L, Di Palma AM, Morrone LF, Strippoli GF, Schena FP |title=The Italian experience of the national registry of renal biopsies |journal=Kidney Int. |volume=66 |issue=3 |pages=890–4 |date=September 2004 |pmid=15327376 |doi=10.1111/j.1523-1755.2004.00831.x |url=}}</ref> | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Secondary (AA) Amyloidosis]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Secondary (AA) Amyloidosis]]''' | ||
| | | | ||
Line 147: | Line 198: | ||
* Biopsy and congo-red staining of the sample | * Biopsy and congo-red staining of the sample | ||
| | | | ||
* Treatment of the undelying | * Treatment of the undelying inflammatory disorder | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Primary (AL) Amyloidosis]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Primary (AL) Amyloidosis]]''' | ||
Line 389: | Line 440: | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Therapy}} | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Therapy}} | ||
|- | |- | ||
| rowspan="6" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Polyneuropathy''' | | rowspan="6" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Polyneuropathy'''<ref name="pmid18615140">{{cite journal| author=Marchettini P, Lacerenza M, Mauri E, Marangoni C| title=Painful peripheral neuropathies. | journal=Curr Neuropharmacol | year= 2006 | volume= 4 | issue= 3 | pages= 175-81 | pmid=18615140 | doi= | pmc=2430688 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18615140 }} </ref><ref name="pmid26141332">{{cite journal| author=Watson JC, Dyck PJ| title=Peripheral Neuropathy: A Practical Approach to Diagnosis and Symptom Management. | journal=Mayo Clin Proc | year= 2015 | volume= 90 | issue= 7 | pages= 940-51 | pmid=26141332 | doi=10.1016/j.mayocp.2015.05.004 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26141332 }} </ref><ref name="pmid11859051">{{cite journal| author=Hughes RA| title=Peripheral neuropathy. | journal=BMJ | year= 2002 | volume= 324 | issue= 7335 | pages= 466-9 | pmid=11859051 | doi= | pmc=1122393 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11859051 }} </ref><ref name="pmid28205574">{{cite journal| author=Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D et al.| title=Neuropathic pain. | journal=Nat Rev Dis Primers | year= 2017 | volume= 3 | issue= | pages= 17002 | pmid=28205574 | doi=10.1038/nrdp.2017.2 | pmc=5371025 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28205574 }} </ref><ref name="pmid27158461">{{cite journal| author=Juster-Switlyk K, Smith AG| title=Updates in diabetic peripheral neuropathy. | journal=F1000Res | year= 2016 | volume= 5 | issue= | pages= | pmid=27158461 | doi=10.12688/f1000research.7898.1 | pmc=4847561 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27158461 }} </ref><ref name="pmid16461471">{{cite journal| author=Bansal V, Kalita J, Misra UK| title=Diabetic neuropathy. | journal=Postgrad Med J | year= 2006 | volume= 82 | issue= 964 | pages= 95-100 | pmid=16461471 | doi=10.1136/pgmj.2005.036137 | pmc=2596705 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16461471 }} </ref><ref name="pmid27637963">{{cite journal| author=Hanewinckel R, Ikram MA, Van Doorn PA| title=Peripheral neuropathies. | journal=Handb Clin Neurol | year= 2016 | volume= 138 | issue= | pages= 263-82 | pmid=27637963 | doi=10.1016/B978-0-12-802973-2.00015-X | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27637963 }} </ref><ref name="pmid219931">{{cite journal| author=Argov Z, Mastaglia FL| title=Drug-induced peripheral neuropathies. | journal=Br Med J | year= 1979 | volume= 1 | issue= 6164 | pages= 663-6 | pmid=219931 | doi= | pmc=1598252 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=219931 }} </ref><ref name="pmid24195230">{{cite journal| author=Remiche G, Kadhim H, Maris C, Mavroudakis N| title=[Peripheral neuropathies, from diagnosis to treatment, review of the literature and lessons from the local experience]. | journal=Rev Med Brux | year= 2013 | volume= 34 | issue= 4 | pages= 211-20 | pmid=24195230 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24195230 }} </ref><ref name="pmid7745415">{{cite journal| author=Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern JP| title=Peripheral neuropathy associated with simvastatin. | journal=J Neurol Neurosurg Psychiatry | year= 1995 | volume= 58 | issue= 5 | pages= 625-8 | pmid=7745415 | doi= | pmc=1073498 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7745415 }} </ref><ref name="pmid2153610">{{cite journal| author=Cohen JA, Gross KF| title=Peripheral neuropathy: causes and management in the elderly. | journal=Geriatrics | year= 1990 | volume= 45 | issue= 2 | pages= 21-6, 31-4 | pmid=2153610 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2153610 }} </ref> | ||
|'''[[POEMS syndrome]] (Demyelinating)''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[POEMS syndrome]] (Demyelinating)''' | ||
| | | | ||
* [[Monoclonal]] [[plasma cell]] proliferation | * [[Monoclonal]] [[plasma cell]] proliferation | ||
Line 411: | Line 462: | ||
| | | | ||
|- | |- | ||
|'''[[Metabolic syndrome|Metabolic Syndrome]] (Axonal pathology)''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Metabolic syndrome|Metabolic Syndrome]] (Axonal pathology)''' | ||
| | | | ||
* [[Diabetes mellitus]] | * [[Diabetes mellitus]] | ||
Line 438: | Line 489: | ||
* [[Foot care]] | * [[Foot care]] | ||
|- | |- | ||
|'''[[Vitamin deficiencies|Vitamin Deficiencies]] (Axonal Pathology)''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Vitamin deficiencies|Vitamin Deficiencies]] (Axonal Pathology)''' | ||
| | | | ||
* [[Vitamin B12 deficiency]] (Decreased [[S-Adenosyl methionine|S-adenosyl methionine]]) | * [[Vitamin B12 deficiency]] (Decreased [[S-Adenosyl methionine|S-adenosyl methionine]]) | ||
Line 464: | Line 515: | ||
* [[Vitamin B12]] supplement ([[parenteral]]) | * [[Vitamin B12]] supplement ([[parenteral]]) | ||
|- | |- | ||
|'''[[Guillain-Barré syndrome|Guillain-Barre Syndrome]] (Demyelinating)''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Guillain-Barré syndrome|Guillain-Barre Syndrome]] (Demyelinating)''' | ||
| | | | ||
* [[Anti-ganglioside antibodies|Anti-ganglioside]] and anti-[[myelin]] antibodies | * [[Anti-ganglioside antibodies|Anti-ganglioside]] and anti-[[myelin]] antibodies | ||
Line 498: | Line 549: | ||
* [[DVT]]/[[PE]] [[prevention]] | * [[DVT]]/[[PE]] [[prevention]] | ||
|- | |- | ||
|'''[[Chronic inflammatory demyelinating polyneuropathy|Chronic Inflammatory Demyelinating Polyneuropathy]] (CIDP) (Mixed axonal and demyelinatiing)''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Chronic inflammatory demyelinating polyneuropathy|Chronic Inflammatory Demyelinating Polyneuropathy]] (CIDP) (Mixed axonal and demyelinatiing)''' | ||
| | | | ||
* Abnormal [[immune response]] (both [[Immunoglobulin G|IgG]] based [[Humoral immunity|humoral]] and [[Cell mediated immunity|T-Cell mediated]]) response to unknown [[antigen]] (possible culprits include [[myelin]] [[proteins]] P0, P2 and PMP22) | * Abnormal [[immune response]] (both [[Immunoglobulin G|IgG]] based [[Humoral immunity|humoral]] and [[Cell mediated immunity|T-Cell mediated]]) response to unknown [[antigen]] (possible culprits include [[myelin]] [[proteins]] P0, P2 and PMP22) | ||
Line 524: | Line 575: | ||
* [[Immunosupressive drug|Immunosupressants]] ([[Alemtuzumab|Alemtuzemab]] [[Azathioprine]] [[Cyclophosphamide]] [[Cyclosporine|Cyclosporin]] [[Etanercept]] [[Interferon-alpha]]) | * [[Immunosupressive drug|Immunosupressants]] ([[Alemtuzumab|Alemtuzemab]] [[Azathioprine]] [[Cyclophosphamide]] [[Cyclosporine|Cyclosporin]] [[Etanercept]] [[Interferon-alpha]]) | ||
|- | |- | ||
|'''[[Multifocal motor neuropathy|Multifocal Motor Neuropathy]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Multifocal motor neuropathy|Multifocal Motor Neuropathy]]''' | ||
| | | | ||
* [[Immune response|Abnormal immune response]] ([[Anti-ganglioside antibodies|Anti ganglioside]] [[Anti-ganglioside antibodies|GM-1]] [[IgM]] [[antibodies]]) | * [[Immune response|Abnormal immune response]] ([[Anti-ganglioside antibodies|Anti ganglioside]] [[Anti-ganglioside antibodies|GM-1]] [[IgM]] [[antibodies]]) | ||
Line 552: | Line 603: | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Therapy'''}} | | style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Therapy'''}} | ||
|- | |- | ||
| rowspan="7" |'''Organomegaly (Hepatosplenomegaly and Lymphadenopathy)''' | | rowspan="7" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Organomegaly (Hepatosplenomegaly and Lymphadenopathy)'''<ref>Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:77 ISBN 1591032016</ref><ref>Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:68 ISBN 140510368X</ref> | ||
|'''[[Malaria]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Malaria]]'''<ref name="RBMarmenia">[http://www.malaria.am/eng/pathogenesis.php Malaria life cycle & pathogenesis]. Malaria in Armenia. Accessed October 31, 2006.</ref> | ||
| | | | ||
* [[Plasmodium falciparum]] | * [[Plasmodium falciparum]] | ||
Line 591: | Line 642: | ||
** [[Atovaquone-Proguanil|Atovaquone plus proguanil]] | ** [[Atovaquone-Proguanil|Atovaquone plus proguanil]] | ||
|- | |- | ||
|'''[[Kala-azar]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Kala-azar]]'''<ref>Kahan, Scott, Smith, Ellen G. In a page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:157</ref> | ||
| | | | ||
* [[Leishmaniasis|Leshmania donovani]] | * [[Leishmaniasis|Leshmania donovani]] | ||
Line 616: | Line 667: | ||
* [[Pentamidine]] | * [[Pentamidine]] | ||
|- | |- | ||
|'''[[Hepatitis|Infective Hepatitis]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Hepatitis|Infective Hepatitis]]''' | ||
| | | | ||
* [[Hepatitis A virus|Hepatitis A virus (HAV)]] | * [[Hepatitis A virus|Hepatitis A virus (HAV)]] | ||
Line 653: | Line 704: | ||
* [[Antivirals|Nucleotide analogs]] | * [[Antivirals|Nucleotide analogs]] | ||
|- | |- | ||
|'''[[Chronic myelogenous leukemia|Chronic Myelogenous Leukemia]] (CML)''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Chronic myelogenous leukemia|Chronic Myelogenous Leukemia]] (CML)'''<ref name="pmid9012696">{{cite journal |vauthors=Savage DG, Szydlo RM, Goldman JM |title=Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period |journal=Br. J. Haematol. |volume=96 |issue=1 |pages=111–6 |date=January 1997 |pmid=9012696 |doi= |url=}}</ref><ref name="pmid26434969">{{cite journal |vauthors=Thompson PA, Kantarjian HM, Cortes JE |title=Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015 |journal=Mayo Clin. Proc. |volume=90 |issue=10 |pages=1440–54 |date=October 2015 |pmid=26434969 |pmc=5656269 |doi=10.1016/j.mayocp.2015.08.010 |url=}}</ref> | ||
| | | | ||
* [[Philadelphia chromosome|BCR/ABL gene]] fusion product due to [[Chromosomal translocation|translocation]] [[mutation]] [[Philadelphia chromosome|t(9;22)]](q34;q11) | * [[Philadelphia chromosome|BCR/ABL gene]] fusion product due to [[Chromosomal translocation|translocation]] [[mutation]] [[Philadelphia chromosome|t(9;22)]](q34;q11) | ||
Line 697: | Line 748: | ||
* [[Stem cell transplantation]] | * [[Stem cell transplantation]] | ||
|- | |- | ||
|'''[[Lymphoma]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Lymphoma]]''' | ||
| | | | ||
* Various causes based on type: | * Various causes based on type: | ||
Line 718: | Line 769: | ||
| | | | ||
|- | |- | ||
|'''[[Primary amyloidosis|Primary (AL) Amyloidosis]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Primary amyloidosis|Primary (AL) Amyloidosis]]''' | ||
| | | | ||
* Aggregation and deposition of [[immunoglobulin light chains]] that are usually produced by [[plasma cell]] clones | * Aggregation and deposition of [[immunoglobulin light chains]] that are usually produced by [[plasma cell]] clones | ||
Line 738: | Line 789: | ||
* Stem cell transplantation | * Stem cell transplantation | ||
|- | |- | ||
|'''[[Gaucher's disease|Gaucher's Disease]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Gaucher's disease|Gaucher's Disease]]''' | ||
| | | | ||
* [[GBA (gene)|GBA gene]] [[mutation]] | * [[GBA (gene)|GBA gene]] [[mutation]] |
Latest revision as of 15:39, 17 December 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2] Sahar Memar Montazerin, M.D.[3]
Overview
Secondary amyloidosis needs to be differentiated from other conditions causing nephrotic syndrome, hepatosplenomegaly, and peripheral neuropathy.
Differentiating Amyloidosis from other Diseases
- Secondary amyloidosis needs to be differentiated from other conditions causing nephrotic syndrome, hepatosplenomegaly, and peripheral neuropathy.
- Also, secondary amyloidosis should be differentiated from other types of amyloidosis, including:[1][2]
Amyloisosis subtype | Protein | Organ involvement (%) | ||
---|---|---|---|---|
Kidney | Liver | Heart | ||
Primary | Monoclonal immunoglobulin light chains | 50-100 | 10-25 | 50-100 |
Secondary | Serum amyloid A | 50-100 | <10 | _ |
Hereditary | Transthyretin (mutated) | <10 | _ | 25-50 |
DRA (dialysis related amyloidosis) | Beta‐2 microglobulin | _ | _ | _ |
Senile systemic (cardiac) amyloidosis | Transthyretin (wild type) | _ | _ | 50-100 |
Meretoja syndrome | Gelsolin | _ | _ | _ |
- Tables below provide information on the differential diagnosis of secondary amyloidosis.
Differential diagnosis of secondary amyloidosis | ||
Nephrotic syndrome causes[3][4][5][6][7][8][9] | ||
| ||
| ||
| ||
| ||
| ||
Hepatosplenomegaly causes[10][11] |
|
|
|
| |
|
||
|
||
|
||
Peripheral neuropathy causes[12][13][14][15][16][17][18][19][20][21][22] |
|
|
|
||
|
||
|
||
|
||
|
Organ System Involvement | Differential Diagnosis | Causes | Clinical Features | Laboratory Findings | Gold Standard Test | Therapy |
---|---|---|---|---|---|---|
Nephrotic Syndrome and Renal Failure[3][4][5][6][7][8][9] | Secondary (AA) Amyloidosis |
|
|
|
|
|
Primary (AL) Amyloidosis |
|
|
|
|||
Diabetic Nephropathy |
|
|
|
|||
Minimal Change Disease |
|
| ||||
Focal Segmental Glomerulosclerosis | ||||||
Fabry's Disease |
|
|
|
|
| |
Light Chain Deposition Disease |
|
|
| |||
Membranous Glomerulonephritis |
|
|
|
|
| |
Fibrillary-Immunotactoid Glomerulopathy |
|
|
|
|||
Organ System Involvement | Differential Diagnosis | Causes | Clinical Features | Laboratory Findings | Gold Standard Test | Therapy |
Polyneuropathy[12][13][14][15][16][17][18][19][20][21][22] | POEMS syndrome (Demyelinating) |
|
|
|||
Metabolic Syndrome (Axonal pathology) |
|
|
|
|||
Vitamin Deficiencies (Axonal Pathology) |
|
|
|
| ||
Guillain-Barre Syndrome (Demyelinating) |
|
|
|
|||
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Mixed axonal and demyelinatiing) |
|
|
|
|
||
Multifocal Motor Neuropathy |
|
|||||
Organ System Involvement | Differential Diagnosis | Causes | Features | Laboratory Findings | Gold Standard Test | Therapy |
Organomegaly (Hepatosplenomegaly and Lymphadenopathy)[23][24] | Malaria[25] |
|
|
| ||
Kala-azar[26] |
|
|
|
|||
Infective Hepatitis |
|
|
||||
Chronic Myelogenous Leukemia (CML)[27][28] |
|
|
||||
Lymphoma |
|
|
||||
Primary (AL) Amyloidosis |
|
|
|
| ||
Gaucher's Disease |
|
|
|
|
References
- ↑ Real de Asua, Diego; Galvan, Jose Maria; Filigghedu, Maria Teresa; Trujillo, Davinia; Costa, Ramon; Cadinanos, Julen (2014). "Systemic AA amyloidosis: epidemiology, diagnosis, and management". Clinical Epidemiology: 369. doi:10.2147/CLEP.S39981. ISSN 1179-1349.
- ↑ Mollee, P.; Renaut, P.; Gottlieb, D.; Goodman, H. (2014). "How to diagnose amyloidosis". Internal Medicine Journal. 44 (1): 7–17. doi:10.1111/imj.12288. ISSN 1444-0903.
- ↑ 3.0 3.1 Rivera F, López-Gómez JM, Pérez-García R (September 2004). "Clinicopathologic correlations of renal pathology in Spain". Kidney Int. 66 (3): 898–904. doi:10.1111/j.1523-1755.2004.00833.x. PMID 15327378.
- ↑ 4.0 4.1 Haas M, Meehan SM, Karrison TG, Spargo BH (November 1997). "Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997". Am. J. Kidney Dis. 30 (5): 621–31. PMID 9370176.
- ↑ 5.0 5.1 Simon P, Ramee MP, Boulahrouz R, Stanescu C, Charasse C, Ang KS, Leonetti F, Cam G, Laruelle E, Autuly V, Rioux N (September 2004). "Epidemiologic data of primary glomerular diseases in western France". Kidney Int. 66 (3): 905–8. doi:10.1111/j.1523-1755.2004.00834.x. PMID 15327379.
- ↑ 6.0 6.1 Braden GL, Mulhern JG, O'Shea MH, Nash SV, Ucci AA, Germain MJ (May 2000). "Changing incidence of glomerular diseases in adults". Am. J. Kidney Dis. 35 (5): 878–83. PMID 10793022.
- ↑ 7.0 7.1 Malafronte P, Mastroianni-Kirsztajn G, Betônico GN, Romão JE, Alves MA, Carvalho MF, Viera Neto OM, Cadaval RA, Bérgamo RR, Woronik V, Sens YA, Marrocos MS, Barros RT (November 2006). "Paulista Registry of glomerulonephritis: 5-year data report". Nephrol. Dial. Transplant. 21 (11): 3098–105. doi:10.1093/ndt/gfl237. PMID 16968733.
- ↑ 8.0 8.1 Bahiense-Oliveira M, Saldanha LB, Mota EL, Penna DO, Barros RT, Romão-Junior JE (February 2004). "Primary glomerular diseases in Brazil (1979-1999): is the frequency of focal and segmental glomerulosclerosis increasing?". Clin. Nephrol. 61 (2): 90–7. PMID 14989627.
- ↑ 9.0 9.1 Gesualdo L, Di Palma AM, Morrone LF, Strippoli GF, Schena FP (September 2004). "The Italian experience of the national registry of renal biopsies". Kidney Int. 66 (3): 890–4. doi:10.1111/j.1523-1755.2004.00831.x. PMID 15327376.
- ↑ Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:77 ISBN 1591032016
- ↑ Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:68 ISBN 140510368X
- ↑ 12.0 12.1 Marchettini P, Lacerenza M, Mauri E, Marangoni C (2006). "Painful peripheral neuropathies". Curr Neuropharmacol. 4 (3): 175–81. PMC 2430688. PMID 18615140.
- ↑ 13.0 13.1 Watson JC, Dyck PJ (2015). "Peripheral Neuropathy: A Practical Approach to Diagnosis and Symptom Management". Mayo Clin Proc. 90 (7): 940–51. doi:10.1016/j.mayocp.2015.05.004. PMID 26141332.
- ↑ 14.0 14.1 Hughes RA (2002). "Peripheral neuropathy". BMJ. 324 (7335): 466–9. PMC 1122393. PMID 11859051.
- ↑ 15.0 15.1 Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D; et al. (2017). "Neuropathic pain". Nat Rev Dis Primers. 3: 17002. doi:10.1038/nrdp.2017.2. PMC 5371025. PMID 28205574.
- ↑ 16.0 16.1 Juster-Switlyk K, Smith AG (2016). "Updates in diabetic peripheral neuropathy". F1000Res. 5. doi:10.12688/f1000research.7898.1. PMC 4847561. PMID 27158461.
- ↑ 17.0 17.1 Bansal V, Kalita J, Misra UK (2006). "Diabetic neuropathy". Postgrad Med J. 82 (964): 95–100. doi:10.1136/pgmj.2005.036137. PMC 2596705. PMID 16461471.
- ↑ 18.0 18.1 Hanewinckel R, Ikram MA, Van Doorn PA (2016). "Peripheral neuropathies". Handb Clin Neurol. 138: 263–82. doi:10.1016/B978-0-12-802973-2.00015-X. PMID 27637963.
- ↑ 19.0 19.1 Argov Z, Mastaglia FL (1979). "Drug-induced peripheral neuropathies". Br Med J. 1 (6164): 663–6. PMC 1598252. PMID 219931.
- ↑ 20.0 20.1 Remiche G, Kadhim H, Maris C, Mavroudakis N (2013). "[Peripheral neuropathies, from diagnosis to treatment, review of the literature and lessons from the local experience]". Rev Med Brux. 34 (4): 211–20. PMID 24195230.
- ↑ 21.0 21.1 Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern JP (1995). "Peripheral neuropathy associated with simvastatin". J Neurol Neurosurg Psychiatry. 58 (5): 625–8. PMC 1073498. PMID 7745415.
- ↑ 22.0 22.1 Cohen JA, Gross KF (1990). "Peripheral neuropathy: causes and management in the elderly". Geriatrics. 45 (2): 21–6, 31–4. PMID 2153610.
- ↑ Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:77 ISBN 1591032016
- ↑ Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:68 ISBN 140510368X
- ↑ Malaria life cycle & pathogenesis. Malaria in Armenia. Accessed October 31, 2006.
- ↑ Kahan, Scott, Smith, Ellen G. In a page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:157
- ↑ Savage DG, Szydlo RM, Goldman JM (January 1997). "Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period". Br. J. Haematol. 96 (1): 111–6. PMID 9012696.
- ↑ Thompson PA, Kantarjian HM, Cortes JE (October 2015). "Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015". Mayo Clin. Proc. 90 (10): 1440–54. doi:10.1016/j.mayocp.2015.08.010. PMC 5656269. PMID 26434969.